Nanobiotix, a late-clinical stage biotechnology company pioneering physics-based approaches to treat cancer, entered into a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3. NBTXR3 is currently being evaluated in several studies across solid tumor indications including NANORAY-312, a global Phase 3 study ev...